Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ANNX | US
-0.23
-3.88%
Healthcare
Biotechnology
30/06/2024
30/08/2024
5.70
5.97
6.04
5.66
Annexon Inc. a clinical-stage biopharmaceutical company discovers and develops therapeutics for autoimmune neurodegenerative and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005 a monoclonal antibody which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007 which is in Phase II clinical trials to treat patients with geographic atrophy. In addition it develops ANX105 an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502 an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
34.4%1 month
56.3%3 months
99.0%6 months
99.8%-
-
1.66
0.08
0.07
-2.47
-
-
-124.79M
602.23M
602.23M
-
-
-
-
-42.20
5.74
8.24
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.64
Range1M
1.56
Range3M
2.99
Rel. volume
0.63
Price X volume
3.50M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Entrada Therapeutics Inc. Common Stock | TRDA | Biotechnology | 17.7 | 658.43M | 1.14% | 5.86 | 14.99% |
SIGA Technologies Inc | SIGA | Biotechnology | 9.03 | 644.46M | -1.63% | 7.72 | 0.97% |
Y-Mabs Therapeutics Inc - Ordinary Shares | YMAB | Biotechnology | 14.31 | 637.79M | 2.07% | n/a | 1.34% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.73 | 625.38M | -3.89% | n/a | 44.04% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 12.41 | 617.11M | -1.27% | n/a | 0.00% |
ITOS | ITOS | Biotechnology | 16.85 | 615.39M | -0.06% | n/a | 0.83% |
REGENXBIO Inc | RGNX | Biotechnology | 12.22 | 603.95M | 1.83% | n/a | 45.57% |
UroGen Pharma Ltd | URGN | Biotechnology | 13.91 | 585.81M | -0.64% | n/a | 326.69% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 13.39 | 576.87M | 3.00% | n/a | 3.54% |
Arcturus Therapeutics Ltd | ARCT | Biotechnology | 21.1 | 570.59M | 0.81% | n/a | 11.94% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 23.91 | 621.28M | 1.18% | 14.94 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.48 | 524.97M | 0.55% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 12.45 | 391.86M | -0.16% | 49.80 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 24.03 | 385.84M | 0.33% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.4 | 326.35M | 0.00% | 12.70 | 0.00% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 28.64 | 316.93M | -0.52% | 18.84 | -621.78% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 18.53 | 314.66M | -0.70% | 36.33 | 26.79% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 15.53 | 251.70M | 1.70% | 9.96 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.42 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.47 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 1.66 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 99.04 | 76.13 | Riskier |
Debt to Equity | 0.08 | -2.05 | Expensive |
Debt to Assets | 0.07 | 0.25 | Cheaper |
Market Cap | 602.23M | 4.04B | Emerging |